Pacific Edge (NZE:PEB, ASX:PEB) reported a 6.8% increase in tests processed at its laboratories in the fourth quarter of fiscal 2025 compared with the prior three-month period, according to a Friday filing with the Australian and New Zealand bourses.
Total laboratory throughput rose to 7,577 tests from 7,092 tests between the third and fourth fiscal quarters.
However, total volumes for the full fiscal year ended March declined nearly 12% to 28,894 tests from 32,633 in the prior fiscal year. The decline reflected lower sales force due to the uncertainty over Medicare coverage of Cxbladder, per the filing.
Pacific Edge's shares were up 3% in New Zealand and by 4% in Australia in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。